Technology offers

The OTT-SSPA offers the access service to all the technologies developed by the Andalusian Public Healthcare System, including patents, utility models, know-how and software. This space features all the technologies available in our Catalogue of Technology Offers We include over 50 new offers every year. If you cannot find what you are looking for, you can contact us here.

LACTOPEROXIDASE AS PARKINSON BIOMARKER
A research group from the Andalusian Health System and Sevilla University has developed a new method for the diagnosis of Parkinson.
NANOSTRUCTURES FOR THE DIAGNOSIS OF ALLERGIES TO BETALACTAMIC ANTIBIOTICS
A research group from the Biomedical Research Institute of Málaga (IBIMA) has developed a new method for the diagnosis of amoxicillin-mediated allergic reactions using nanostructures.
BIOMARKERS TO PREDICT RESPONSE TO TREATMENT IN METASTATIC MELANOMA PATIENTS
A research group from the Biomedical Research Institute of Málaga (IBIMA) has developed a new biomarker panel to predict response to treatment in metastatic melanoma patients.
HIGHLY INDUCIBLE TET-ON VECTOR SYSTEM
A research group from the Andalusian Public Health System (SSPA) has developed a TetR(Tetracycline repressor)-based all-in-one lentiviral system
MOLECULAR METHOD THAT RADICALLY IMPROVES THE DIAGNOSIS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
A research group from Andalusian Public Health System has developed a a diagnostic molecular system for the HHT by getting a liquid biopsy from the patient.
POLYNUCLEOTIDE FOR PHYSIOLOGICAL EXPRESSION IN T CELLS
A research group from the Andalusian Public Health System has developed a new system to generate T lymphocytes for use in immunotherapy.
BIOMARKERS FOR NON-INVASIVE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
A research group from the Public Health System of Andalusia has developed a panel of 11 metabolites, whose quantitative analysis offers valuable diagnostic information for PDAC
USE OF BCL7A AS MOLECULAR TARGET FOR DLBCL DRUG SCREENING & DEVELOPMENT
A research team from the Andalusian Health System has demonstrated that BCL7A plays a tumor suppressor role in Diffuse large B cell lymphoma (DLBCL) which reveals new prognostic and therapeutic opportunities for the treatment of DLBCL patients.
USE OF BCL7A AS MOLECULAR TARGET FOR DLBCL DRUG SCREENING & DEVELOPMENT
A research team from the Andalusian Health System has demonstrated that BCL7A plays a tumor suppressor role in Diffuse large B cell lymphoma (DLBCL) which reveals new prognostic and therapeutic opportunities for the treatment of DLBCL patients.
GENE THERAPY WITH HOKD AND LDRB GENES FOR CANCER TREATMENT
A research group of the Public Health System of Andalusia (SSPA) has developed an alternative technology, based on the transfection of hokD and ldrB genes, to be used in cancer gene therapy.

Pages